- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Over Rs 2 Cr Semaglutide Theft at Dr Reddy's Srikakulam Unit, Staff Among 8 Arrested

Srikakulam: In a serious breach of supply chain and internal controls, a group of eight individuals, including current and former pharmaceutical staff, have been apprehended for allegedly stealing semaglutide powder worth over Rs 2 crore from Dr. Reddy's Laboratories' API manufacturing unit in Andhra Pradesh.
The incident took place at the pharma major’s SEZ facility in Pydibhimavaram, Srikakulam district. The theft reportedly occurred over multiple instances and involved the diversion of semaglutide, a high-value active pharmaceutical ingredient (API) used in the manufacture of anti-diabetic and weight loss drugs such as Ozempic and Wegovy.
According to police officials quoted in Times of India, the suspects include an active employee from the formulation plant, a former staffer from the warehouse team, and six others who colluded to smuggle the material and channel it into the black market.
Also Read: Delhi HC Restrains Dr Reddy's from Selling Semaglutide Drug in India Amid Novo Nordisk Row
An official from the police investigation stated, “An employee working in the formulation block and a former staffer in the warehouse played a key role. Six others collaborated with them in executing the theft.”
The gang reportedly sold the diverted API to unauthorized buyers in major metros like Mumbai and Chennai. The culprits allegedly packed the stolen semaglutide in food delivery containers to avoid detection while transporting it out of the premises.
Initial reports suggest that multiple kilograms of the product had already been trafficked before the matter came to light. Based on internal audits and inventory checks, the pharmaceutical company lodged a formal complaint, prompting police to launch an investigation.
“They smuggled the powder in food delivery containers to avoid suspicion and sold it in cities like Mumbai and Chennai,” the police added.
Dr. Reddy’s Laboratories has not yet released a formal public statement on the matter. However, TOI reports that industry insiders say that such internal breaches in high-value API manufacturing facilities underscore the need for enhanced surveillance and stricter material accountability protocols.
The pharmaceutical industry, particularly those involved in GLP-1 agonist API production, has taken note of the incident, as semaglutide continues to remain in high global demand and commands a premium price across regulated and semi-regulated markets.
Law enforcement authorities are continuing further investigation, and more arrests are expected in connection with the illegal diversion of pharmaceutical-grade semaglutide.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751